Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia

J Infect. 2013 Mar;66(3):294-6. doi: 10.1016/j.jinf.2012.11.010. Epub 2012 Nov 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Case-Control Studies
  • Drug Resistance, Bacterial*
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / microbiology
  • Ertapenem
  • Escherichia coli / drug effects*
  • Escherichia coli / enzymology
  • Female
  • Humans
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / enzymology
  • Male
  • Meropenem
  • Microbial Sensitivity Tests
  • Middle Aged
  • Risk Factors
  • Thienamycins / pharmacology
  • Thienamycins / therapeutic use
  • Treatment Outcome
  • beta-Lactams / pharmacology
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Thienamycins
  • beta-Lactams
  • Meropenem
  • Ertapenem